Results for aspergillosis translation from English to Estonian

aspergillosis,
aspergilloos,

invasive aspergillosis
invasiivne aspergilloos

treatment of invasive aspergillosis
invasiivse aspergilloosi ravi

for the treatment of aspergillosis.
aspergilloosi ravi.

invasive aspergillosis in adult patients:
invasiinvne aspergilloos täiskasvanud patsientidel.

this infection is named invasive aspergillosis.
seda infektsiooni nimetatakse invasiivseks aspergilloosiks.

- aspergillosis (a fungus-related lung disease)
- aspergilloos (kopsu seennakkus)

aspergillus infections – efficacy in aspergillosis patients with poor prognosis
aspergillus-infektsioonid – efektiivsus halva prognoosiga aspergilloosipatsientidel

in both prophylaxis studies, aspergillosis was the most common breakthrough infection.
mõlemas profülaktika uuringus oli sagedasem lisandunud infektsioon aspergilloos.

- invasive aspergillosis in patients with disease that is refractory to amphotericin b or
- invasiivne aspergilloos patsientidel, kui haigus ei allu ravile amfoteritsiin b või itrakonasooliga,

invasive aspergillosis and mucormycosis are life-threatening infections associated with high mortality.
invasiivne aspergilloos ja mukormükoos on eluohtlikud infektsioonid, mida seostatakse suure suremusega.

the most commonly treated fungal infection was aspergillosis (43/ 61; 70%).
84 farmakokineetika spetsiifilistel patsientide gruppidel

in studies, cresemba’s effect was comparable to that of voriconazole in treating invasive aspergillosis.
uuringutes peeti cresemba toimet invasiivse aspergilloosi ravis võrreldavaks vorikonasooli toimega.

of these, 37 had invasive candidiasis, 10 had invasive aspergillosis, and 1 patient had esophageal candidiasis.
nendest patsientidest 37-l oli invasiivne kandidiaas, 10-l invasiivne aspergilloos ja 1-l söögitoru kandidiaas.

aspergillus infections – efficacy in aspergillosis patients with poor prognosis voriconazole has in vitro fungicidal activity against aspergillus spp.
aspergillus-infektsioonid – efektiivsus halva prognoosiga aspergilloosihaigetel vorikonasool avaldab in vitro antifungitsiidset toimet aspergillus spp. suhtes.

the study included 107 patients with aspergillosis, 18 patients with fusariosis, 11 with chromoblastomycosis or mycotema, and 16 with coccidioidomycosis.
uuringus osales 107 aspergilloosiga, 18 fusarioosiga, 11 kromoblastomükoosi või mütsetoomiga ja 16 koktsidioidmükoosiga patsienti.

aspergillosis: 5 to 10 mg (0.5 ml to 1 ml) itraconazole per kg bodyweight per day for 8 weeks.
aspergilloos: 5–10 mg (0,5–1 ml) itrakonasooli kehamassi kg kohta ööpäevas 8 nädala vältel.

fungitraxx is used to treat ornamental birds with two types of fungal infections of the respiratory tract (aspergillosis and candidiasis).
fungitraxxi kasutatakse ilulindudel kahte tüüpi hingamisteede infektsioonide (aspergilloos ja kandidoos) raviks.

also reported in patients with invasive aspergillosis were pulmonary oedema, adult respiratory distress syndrome (ards), and radiographic infiltrates.
invasiivse aspergilloosi patsientidel on esinenud kopsuturset, täiskasvanute respiratoorse distressi sündroomi ja radioloogilistel uuringutel sedastatavaid infiltraate.

the studies included cerebral, sinus, pulmonary and disseminated aspergillosis in patients with bone marrow and solid organ transplants, haematological malignancies, cancer and aids.
ravi kestus kliinilistes uuringutes vältas vorikonasoolravi 561 patsiendil enam kui 12 nädalat, neist 136- l enam kui 6 kuud.